The compounding pharmacy acquired Taylors Pharmacy and Key Compounding Pharmacy.
Stock.adobe.com
Revelation Pharma announced that it has acquired Taylors Pharmacy and Key Compounding Pharmacy.1 The former company is a nationwide pharmacy based in Florida, while the latter is based in the state of Washington. These acquisitions will further Revelation’s coast-to-coast expansion.
Revelation is a national network of 503A and 503B compounding pharmacies.
In a press release, Revelation Pharma CEO Shawn Hodges said, “At Revelation Pharma, we aim to touch as many lives as possible through our vast range of compounding services. With the addition of Taylors Pharmacy and Key Compounding Pharmacy to the Revelation Pharma compounding network, we will further enhance that goal. We look forward to supporting both pharmacies in their dedication to their patients."
In response to the announcement of the acquisition, Taylors Pharmacy founder Allen Deaver said, “As a pharmacy of humble beginnings, expanding our services and reaching more patients has been so fulfilling for us every step of the way. Becoming a part of the Revelation Pharma network helps us continue down that path, and we're thrilled for the opportunity."
Key Compounding Pharmacy owner HeeJoo Park added, “To join the Revelation Pharma national network of compounding pharmacies is a big step for us, especially as we look to the future in how we support our patients who have come to rely on us over the years. We're excited for what's to come by this addition to the Key Compounding Pharmacy story."
Revelation Pharma has been expanding its network for several years. In January of 2022, the company completed five acquisitions, including Innovation Compounding in Georgia, Pencol Compounding in Colorado, Pharmacy Specialists Compounding in Florida, Wise Pharmacy in Colorado, and Convex Pharmacy in Illinois.2
In a press release issued at the time, Revelation Pharma’s chairman Jake Beckel said, “We're excited to welcome Innovation, Pencol, Pharmacy Specialists, Wise and Convex to the Revelation platform. These partnerships add to our expertise in a wide variety of innovative therapies, and we remain focused on looking for new acquisitions to expand our capabilities and better serve our customers.”
In the same press release, Osceola Capital partner Ben Moe also said, “These acquisitions are highly strategic to the Revelation platform–expanding our geographic reach to key areas of the US and adding talented leadership to the business. We look forward to continuing an aggressive acquisition growth strategy and partnering with best-in-class compounding pharmacies nationwide."
Revelation Pharma has also expanded its nationwide network with new products. In May of this year, the company announced ConsultRX, a nationwide VIP service that utilizes with virtual clinical consulting.3
In a press release issued at the time, Revelation Pharma vice president of clinical and marketing services Tara Thompson, PharmD, FAPC, said, “The development of ConsultRX was a natural, organic move as it aligns with our commitment to delivering best-of-the-best care, which benefits patients and healthcare providers alike. Our team's passion for solving various healthcare issues in a compounding setting is our foremost priority, and we're confident ConsultRX in its consulting capabilities, will further our ability to achieve that."
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.